It was a Tuesday morning in Q1 2024, and I was staring at a stack of 12-page brochures for a Fraxel laser promotional kit. The marketing team was excited—this was the big push for a new skin tone evening treatment campaign. The clinical data was solid, the before-and-after results were impressive, and the copy was… well, mostly clean.
Mostly.
I caught it on page 8, in the small print under a table about laser texture improvement. The spec said the Fraxel 1927 wavelength could treat ‘all skin types’ without qualification. That’s a problem. Fraxel 1927 is excellent for skin tone evening, but ‘all skin types’ is a claim that needs a huge asterisk, especially when you're talking about treating darker skin tones. We had the clinical evidence to support a claim, but it was nuanced. The brochure made it sound absolute.
I flagged it. The project lead pushed back. “The competitor’s brochure says that.” My response: “FTC guidelines don’t care what the competitor’s brochure says.”
We argued for a day. I pulled up the FTC guidance on advertising claims—per FTC guidelines (ftc.gov), claims must be ‘truthful and not misleading’ and ‘substantiated with evidence.’ A claim of ‘all skin types’ without the right context? That’s a red flag for a compliance review. It wasn't just about being safe; it was about being precise. If a clinic used that brochure and a patient had a reaction, the blame doesn’t fall on the copywriter—it falls on the brand.
The team relented. We rewrote that specific claim to say ‘effective for a broad range of skin types, including many previously underserved by laser treatments, when used by a qualified provider.’ Longer. Less punchy. But defensible.
I thought that was the end of it.
Fast forward to the client launch. The brochures went out—5,000 units to our top provider network. I was getting ready for the next project when the compliance director called me. Someone had filed a grievance about an ad from another region that used similar absolute language. It wasn’t our brochure, but it was close. The director asked to see our final approval files for the Fraxel kit.
I pulled the file. Our revised version was there. Thank god.
But the near-miss scared me. What if I hadn’t caught it? What if the team had overruled me? The cost of a reprint on 5,000 units is roughly $18,000 (that’s my estimate for a 12-page, full-color booklet, give or take a few hundred). Plus the delay. Plus the damage to the Fraxel brand reputation. The upside was a slightly more punchy line. The risk was a regulatory nightmare. I kept asking myself: is a punchy line worth potentially costing us $18,000 and a credibility hit?
That experience changed how I review materials. Now, every piece of content—from a product spec sheet to a social post—gets a ‘Precision Check.’ It’s a 12-point list I created after that incident. It includes verifying claims against clinical evidence, checking for absolute language, and ensuring tone matches the brand voice. It sounds overly bureaucratic, but it saved us on a recent Thermage project. A draft claimed results were ‘permanent.’ That’s a big no-no. Our checklist flagged it immediately.
I'm not a marketing strategist, so I can't speak to the 'art' of selling. But from a quality perspective, the most persuasive content is content that is defensible. A statistic from the Fraxel clinical study is way more powerful than ‘everyone loves it.’
This was accurate as of Q1 2024. The regulatory landscape changes fast, so verify current standards before your next big launch. But the principle remains: five minutes of verification beats five days of correction every single time. And sometimes, it saves you from a recall that costs more than the entire print run.
